Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma.

5 Mar 2012

National Council for Research on Women honors CINJ breast oncologist

The chief medical officer at The Cancer Institute of New Jersey (CINJ) has been named as one of this year's 30 'Outstanding Women' by the National Council for Research on Women. Deborah L. Toppmeyer, MD, a medical oncologist at CINJ who heads a very active breast cancer clinic and conducts clinical research, was selected for her commitment to issues critical to advancing women and women's health.

5 Mar 2012

Astex fourth quarter total revenues increase to $21.2 million

Astex Pharmaceuticals, Inc., today reported financial results for the fourth quarter and year ended December 31, 2011.

5 Mar 2012

FDA accepts Eisai's resubmission of perampanel NDA for review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy.

5 Mar 2012

AMAG fourth quarter total revenues decrease to $14.9 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2011. As of December 31, 2011, the company's cash, cash equivalents and investments totaled approximately $230 million.

5 Mar 2012

Zalicus completes reformulated Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.

5 Mar 2012

FDA clears UELS contactless breast cancer imaging tool

UE LifeSciences Inc. (UELS), a medical device manufacturer focused on providing novel breast cancer screening solutions, announced today that it has received market clearance from the U.S. Food and Drug Administration (FDA) for its NoTouch BreastScan™ device. NoTouch BreastScan™ is a contactless breast-imaging tool cleared by the FDA specifically for adjunctive diagnostic screening for the detection of breast cancer.

5 Mar 2012

Varian to acquire InfiMed

Varian Medical Systems, Inc., today announced it has reached an agreement to acquire InfiMed, Inc., a privately-owned, leading supplier of workstations including hardware and software for processing diagnostic X-ray images. The acquisition, which is expected to close in early April subject to the satisfaction of certain closing conditions, will operate within Varian's X-Ray Products segment.

5 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

Access full year 2011 revenues increase 284%

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales.

5 Mar 2012

Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement

Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.

5 Mar 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012

Novel partnership could transform breast cancer diagnosis

An innovative University of Sydney research partnership with private enterprise could see a radical change in how breast cancer is diagnosed, with the possibility to improve detection rates.

4 Mar 2012

Vitamin A daily dose may help prevent skin cancer: Study

A study has shown that a daily vitamin pill could help prevent skin cancer - particularly among women. Scientists say taking food supplements containing vitamin A can make people less likely to develop melanoma, the deadliest form of the disease.

4 Mar 2012

Diesel exhaust fumes linked to lung cancer among miners

It has been known that diesel exhaust may be a probable carcinogen. But the 20-year study from the National Cancer Institute took a closer look in the Diesel Exhaust in Miners Study, which followed 12,315 miners working in eight underground nonmetal mining facilities. Data were collected on the miners' health and exposure to various elements and chemicals from the time when the mine company first introduced diesel-powered equipment (between 1947 and 1967) until the end of the study in 1997. They breathed varying levels of exhaust from diesel-powered equipment, levels higher than the general population encounters.

4 Mar 2012

Dr. Reddy’s introduces generic Geodon in the U.S.

Dr. Reddy's Laboratories announced today that it has launched Ziprasidone Hydrochloride Capsules, a bioequivalent generic version of Geodon in the US market on March 2, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Ziprasidone Hydrochloride Capsules.

3 Mar 2012

Survivors of cancer in childhood have higher risk of infertility in later life

Survivors of cancer in childhood have a higher risk of infertility in later life. This is the conclusion reached by Magdalena Balcerek and her co-authors in a study published in Deutsches -rzteblatt International.

3 Mar 2012

Early surgical intervention stops seizures and improves quality of life

While the thought of any type of surgery can be disconcerting, the thought of brain surgery can be downright frightening. But for people with a particular form of epilepsy, surgical intervention can literally be life-restoring.

3 Mar 2012

CLR01 blocks toxic aggregations of proteins in mouse model of Parkinson's

Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.

2 Mar 2012

Combination of implanted DCs and EBRT effective in creating sarcoma tumor immune response

A team of 18 researchers at Moffitt Cancer Center in Tampa, Fla., have found that treating high-risk, soft tissue sarcoma patients with a combination of implanted dendritic cells (immune system cells) and fractionated external beam radiation (EBRT) provided more than 50 percent of their trial patients with tumor-specific immune responses lasting from 11 to 42 weeks.

2 Mar 2012